THOUSAND OAKS, Calif., Nov. 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2025.
The intervention being tested is AMG 193, an experimental drug administered orally in film-coated tablet form. The purpose of AMG 193 is to treat MTAP-deleted NSCLC by evaluating its safety and ...
Study Design The Phase 1/2 study ( NCT05732831) is a multicenter, open-label, first in human study in solid tumor patients whose tumor has a confirmed homozygous MTAP deletion. The first part of the ...
Contributed by Vern L. Schramm, May 5, 2017 (sent for review March 23, 2017; reviewed by Jiali Gao and Nigel S. Scrutton) TPS calculations predicted that a F159Y mutation in PNP would facilitate ...
La capécitabine est un cytotoxique indiqué dans les cancers du sein et colorectaux. Sa toxicité est majorée chez certains ...
Edited* by Carlo M. Croce, Ohio State University, Columbus, OH, and approved May 17, 2010 (received for review December 9, 2009) ...
You are free to share (copy and redistribute) this article in any medium or format and to adapt (remix, transform, and build upon) the material for any purpose, even commercially within the parameters ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback